Recursion Pharmaceuticals (RXRX) Capital Leases (2020 - 2021)
Recursion Pharmaceuticals (RXRX) reported Capital Leases of $9.3 million for Q4 2021, up 244.87% on a YoY basis from $2.7 million in Q4 2020, and up 169.91% quarter-over-quarter from $3.5 million in Q3 2021.
Recursion Pharmaceuticals (RXRX) Capital Leases (2020 - 2021) Analysis & Trends
Recursion Pharmaceuticals has reported Capital Leases for 2 years, with the latest figure at $9.3 million in Q4 2021.
- For the quarter ending Q4 2021, Capital Leases rose 244.87% year-over-year to $9.3 million; the trailing twelve-month figure through Dec 2021 stood at $9.3 million (up 244.87% YoY), and the FY2021 full-year result was $9.3 million, up 244.87% from the prior year.
- Capital Leases for Q4 2021 stood at $9.3 million, up from $3.5 million in the prior quarter.
- The five-year high for Capital Leases was $9.3 million in Q4 2021, with the low at $2.4 million in Q2 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Recursion Pharmaceuticals | 1.71 Bn | 1.05 Bn | -6.02 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | 9.34 Mn |
| Sep 30, 2021 | 3.46 Mn |
| Jun 30, 2021 | 2.43 Mn |
| Mar 31, 2021 | 2.55 Mn |
| Dec 31, 2020 | 2.71 Mn |